Physiology of Body Lateralization on Regional Lung Ventilation Study (LATLUNGS)

October 25, 2023 updated by: Shirley Lima Campos, University of Pernambuco

Physiological Effects of Lateral Body Positioning on Regional Ventilation and Ultrasound Diaphragmatic Mobility in Healthy Subjects: an Experimental Study

The goal of this experimental study, with crossover design, is to analyze the effects of body lateralization applied at 30 degrees compared to the supine position on the distribution of ventilation and regional lung aeration in healthy individuals.

The main study questions to be answered are:

  • Question 1: What are the immediate effects of 30 degree body lateralization on the distribution of regional ventilation and lung aeration in healthy individuals?
  • Question 2: What is the effect of body lateralization on diaphragmatic mobility in the dependent or non-dependent hemithorax?

Participants will be submitted to changes in positioning in bed, considering a randomized sequence of interventions, between supine position and body lateralization at 30 degrees, using the Multicare bed (Linet, Czech Republic). The interventions were repeated twice each with a 30-minute washout in each sequence.

Participants will perform assessment of lung function and respiratory muscle strength with the instruments:

  • Manovacuometry
  • Spirometry
  • Ventilometry
  • Respiratory Diagnostic Assistant

The supine and body lateralization positions will be compared, with the primary outcomes being lung aeration and ventilation distribution assessed using Electrical Impedance Tomography. The secondary outcome will be diaphragmatic mobility measured through lung ultrasound.

Groups:

  • Supine position
  • Body lateralization

Effects

  • Lung aeration
  • Distribution of ventilation
  • Diaphragmatic mobility

Study Overview

Detailed Description

Body positioning is a therapy used in the hospital environment to improve oxygenation. Recent studies recommend lateralization therapy to improve lung function locally by positioning the chest region of interest upwards. However, there are still gaps in the description of the effects of body lateralization on lung aeration and ventilation between non-dependent and gravity-dependent regions and on diaphragmatic mobility.

The objective of this study is to analyze the acute effects of lateralization on the aeration and distribution of lung ventilation, in comparison with the supine position, in healthy subjects. In addition, the effect of body positioning on diaphragm kinetics was evaluated.

This is a crossover study, which will be carried out at the Hospital das Clínicas of the Federal University of Pernambuco (HC-UFPE). The sample will consist of 30 healthy volunteers, aged between 18 and 59 years, of both sexes.

The change of body position will be performed using the Multicare bed (Linet, Praga,Czech Republic).

Lung ventilation and aeration will be evaluated with an Enlight 1800 electrical impedance tomography (EIT) (Timpel Medical, São Paulo, Brazil). The EIT images will be segmented into four regions of interest (ROIs: anterior right, anterior left, posterior right and posterior left. Diaphragm mobility will be quantified by diaphragmatic ultrasound in the supine and lateral positions.

The study was approved by the Research Ethics Committee of the Hospital das Clínicas of the Federal University of Pernambuco (EBSERH), in accordance with the norms of the National Health Council (Resolution 466/12) for research in human beings (opinion number 5,980.254).

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Recife, Brazil
        • Hospital das clínicas da UFPE
    • Pernambuco
      • Recife, Pernambuco, Brazil, 50740-600
        • Shirley Campos

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy individuals
  • Volunteers aged between 18 and 59 years old (youth/adults)
  • Volunteers of both sexes

Exclusion Criteria:

  • Individuals with contraindications for the use of manovacuometry, spirometry, ventilometry will be excluded
  • Volunteers who did not tolerate the positioning or interventions
  • Individuals with Grade III obesity (BMI > 40)
  • Participants with below-normal prediction values for manovacuometry and spirometry according to predefined formulas for men and women
  • History of flu syndrome in the last seven days.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Supine Positioning
The participant will be in the supine position.
The participant will be guided to the Multicare bed and will be positioned supine with the headboard not tilted. At this point, the participant will already have the EIT electrode belt and head, trunk and lower limb cushions around it, providing stability. After the participant has been correctly positioned, ventilatory monitoring will begin using the EIT. The environment must be fully controlled, that is, with adequate lighting, all collection members in silence, as well as the devices in the place, air-conditioned environment, without exposing the participant to heat or cold. Before starting the collection, the volunteer will be asked to try not to sleep or talk, making it clear that any discomfort can be reported at any time. To keep the volunteer awake, visual and sound stimuli can be performed. Furthermore, if you cough or sigh, the collection will restart. The intervention will last 5 minutes and will be repeated twice, with intervals between body lateralization.
Other Names:
  • Supine
  • Supine Position
Experimental: Body Lateral Positioning
The participant will be in the body lateral position at 30 degrees.
The participant will start from the bench press to the 30-degree lateral position. The cushions placed at the beginning of the collection will provide stability so that the inclination does not compromise the correct positioning of the participant, preventing them from sliding on the bed. Furthermore, it is also a safety measure for the participant. The environment will be controlled throughout the intervention and visual and sound effects will also be performed in lateral positioning. The volunteer will remain in this position for five minutes and shortly after will be placed in the supine position again. To start the protocol for the second and final time, the participant will have a washout time of thirty minutes.
Other Names:
  • Automatic patient positioning
  • Continuous lateral rotation therapy
  • Lateral rotation therapy
  • Continuous rotational therapy
  • Kinetic bed therapy
  • Lateral change Positioning
  • Automated lateral rotation
  • Rotating bed
  • Automatic lateral therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in end-expiratory lung impedance (Delta EELZ)
Time Frame: Not later than 12 months after primary completion date

Lung aeration will be assessed using Electrical Impedance Tomography (EIT). Regional EELZ will be calculated and analyzed concerning intervention times.

The change in aeration distribution or change in end-expiratory lung impedance (Delta EELZ) will be determined by comparing pre- and post-intervention EELZ for lung quadrants and dependent/non-dependent regions in each intervention.

End-expiratory lung impedance (EELZ) represents the sum of the end-expiratory impedance values of the pixels in a given region of interest. Regions of interest include: right anterior, left anterior, right posterior and left posterior, and functionally, dependent or non-dependent lung.

Continuous EIT monitoring will occur, and outcomes will be assessed before and after each intervention, each lasting five minutes.

Data are given in:

  • arbitrary units (a.u.)
  • mililiters
  • percentages
Not later than 12 months after primary completion date
Change in distribution of lung ventilation (Delta Z)
Time Frame: Not later than 12 months after primary completion date

The distribution of lung ventilation will also be assessed using electrical impedance tomography.

The impedance variation (Delta Z) represents the sum of the impedance values of the pixels in a given region of interest. Regions of interest include: right anterior, left anterior, right posterior and left posterior, and functionally, dependent or non-dependent lung.

The change in distribution of lung ventilation will be obtained by the difference between the Delta Z before and after each intervention, comparing the measurements of the lung quadrants and in the dependent and non-dependent lung regions for each intervention.

Continuous EIT monitoring will occur, and outcomes will be assessed before and after each intervention, each lasting five minutes.

Data are given in:

  • arbitrary units (a.u.)
  • mililiters
  • percentages
Not later than 12 months after primary completion date

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in diaphragmatic mobility measured by ultrasound between the supine and body lateralization positions.
Time Frame: Not later than 12 months after primary completion date

Diaphragmatic mobility will be evaluated in the supine position and in the body lateralization position during the intervention using ultrasound, according to protocol from TESTA, A. et al 2011.

Measurements will be carried out with the patient breathing spontaneously in supine and body lateralization position at 30º.

Data are given in:

• Millimeters.

Not later than 12 months after primary completion date

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Respiratory pattern variables
Time Frame: Not later than 12 months after primary completion date

Respiratory pattern variables will be measured by the Respiratory Diagnostic Assistant.

The algorithm of the "Respiratory Diagnostic Assistant" device relates the variables respiratory rate, tidal volume, minute volume, inspiratory flow, expiratory flow, relationship between inspiratory and expiratory times.

Data are given in:

  • Respiratory rate in incursion per minute
  • Tidal volume (measured in liters)
  • Minute volume (measured in liters);
  • Inspiratory flow (measured in liters);
  • Expiratory flow (measured in liters);
  • Ti/Ttotal, (measured in seconds)
  • I:E, relationship between inspiratory and expiratory times
  • Volume vs time;
  • Flow vs time.
Not later than 12 months after primary completion date
Frequency of normal and altered breathing patterns
Time Frame: Not later than 12 months after primary completion date

The frequency of normal and altered breathing patterns will be measured by the Respiratory Diagnostic Assistant.

The "Respiratory Diagnosis Assistant" algorithm provides the classification of the diagnosis of breathing patterns as normal or altered, considering the input variables of flow, volume and time.

  • The normal breathing pattern described in the frequency of cases is when there is no change assessed by the algorithm.
  • The altered breathing pattern described in the frequency of cases are changes in the breathing pattern variables captured by the device's flow sensor during breathing at rest.

Data are given in:

• Absolut and relative frequencies

Not later than 12 months after primary completion date
Lung function measured by Spirometry
Time Frame: Not later than 12 months after primary completion date

Lung function tests are performed by the callibrated spirometer following American Thoracic Society guidelines (2019).

The analysis variables will be:

  • Forced vital capacity (FVC) - given in liters and percentage of predicted value
  • Forced expiratory volume in 1 second - (FEV1) - given in liters and percentage of predicted value
  • Relationship between FVC/FEV1 - given in measured value and percentage of predicted value

Furthermore, it allows you to draw up a functional diagnosis:

  • Normal
  • Obstructive ventilatory disorder (mild, moderate or severe)
  • Restrictive ventilatory disorder (mild, moderate or severe)
  • Mixed ventilatory disorder (with detection of obstructive and restrictive abnormality) Data are given in: Percentages
Not later than 12 months after primary completion date
Lung volumes at rest breathing
Time Frame: Not later than 12 months after primary completion date

Lung volumes at rest breathing will be measured by calibrated ventilometer (Ferraris Mark 8 Wright Respirometer®,. United Kingdom).

Tidal volume (Vt) will be obtained by the ratio between minute volume (MV) and the respiratory rate (RR) observed during one minute of breathing at rest (Vt = MV/RR)

Data are given in:

  • Minute volume (MV) measured in liters per minute;
  • Tidal volume (TV), measured in liters.
Not later than 12 months after primary completion date
Lung capacities
Time Frame: Not later than 12 months after primary completion date

Lung capacities will be measured by calibrated ventilometer (Ferraris Mark 8 Wright Respirometer®,. United Kingdom).

Inspiratory capacity (IC) - It's the maximum volume voluntarily inspired from the end of a spontaneous expiration (from the resting expiratory level).

Slow vital capacity (SVC) - measurement taken slowly, starting from a position of full inspiration for complete exhalation.

Data are given in:

  • Inspiratory capacity - measured in liters
  • Slow vital capacity - measured in liters
Not later than 12 months after primary completion date
Maximum inspiratory pressure (MIP)
Time Frame: Not later than 12 months after primary completion date

Measurement of the maximum static inspiratory pressure that a subject can generate at the mouth measuring inspiratory muscle strength measured by digital manometer (MVD300u, Homed, Brazil)

  • Maximum inspiratory pressure (measured in cmH2O)
  • Maximum predicted inspiratory pressure (predicted %) - MIP predicted =63,27-0,55 (age)+17,96 (sex)+0,58 (weight )

Data are given in:

  • CmH2O
  • percentage of predicted value
Not later than 12 months after primary completion date
Maximum expiratory pressure (MEP)
Time Frame: Not later than 12 months after primary completion date

Measurement of the maximum static expiratory pressure that a subject can generate at the mouth measuring expiratory muscle strength measured by digital manometer (MVD300u, Homed, Brazil)

  • Maximum expiratory pressure (cmH2O)
  • Maximum predicted expiratory pressure (predicted %)

MEP =-61,41+2,29 (age)-0,03 age2)+33,72 (sex)+1,40 (waist)

Data are given in:

  • CmH2O
  • percentage of predicted value
Not later than 12 months after primary completion date

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Layane Santana, University of Pernambuco
  • Principal Investigator: Shirley Campos, University of Pernambuco

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 22, 2023

Primary Completion (Actual)

October 25, 2023

Study Completion (Actual)

October 25, 2023

Study Registration Dates

First Submitted

August 30, 2023

First Submitted That Met QC Criteria

September 12, 2023

First Posted (Actual)

September 21, 2023

Study Record Updates

Last Update Posted (Actual)

October 27, 2023

Last Update Submitted That Met QC Criteria

October 25, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • UFPE 5.980.254

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Participant characteristics Medical history Clinical measurements Functional results Images (USG) Adverse events

IPD Sharing Time Frame

Through study completion, an average of 1 year.

IPD Sharing Access Criteria

Individual participant data (IPD) access will be granted by the PI after request review for approval via email. It will be shared with researchers and general public of interest on the subject for descriptive analyses related to our sample. A committee of researchers will be in charge of discussing the request before approving the access.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Individuals

Clinical Trials on Supine Positioning

Subscribe